Amato Giaccia announced as new director of the Oxford Institute for Radiation Oncology

The Cancer Research UK Oxford Centre is delighted to welcome Professor Amato J Giaccia (recently appointed as the new director of the MRC Oxford Institute for Radiation Oncology) to the Oxford cancer research community.

Professor Giaccia was recruited to the Institute for Radiation Oncology in Oxford after many successful years as director of the Division of Radiation & Cancer Biology at the University of Stanford, California.  He is internationally recognised for his contribution to understanding the role of tumour microenvironment, hypoxia, and HIF-1-mediated pathways in cancer.  He has more than 20 years of experience in Radiation Oncology research with over 200 publications, has been elected to the National Academy of Medicine, and has been honoured with the American Society of Therapeutic Radiation Oncology’s Gold Medal. He also co-authored the widely used textbook “Radiobiology for the Radiologist”.

His distinguished scientific career has garnered him an international standing within the global Radiation Oncology community which, with a wealth directorship experience and global perspective on cancer patient care, ideally places him to lead Oxford’s Radiation Oncology research community. Prof. Giaccia seeks to build on the Institute’s existing expertise, integrate novel multidisciplinary fundamental research across Oxford University, and work with Oxford’s commercial, governmental, academic and charitable partners to ensure that patients across the UK receive the most effective radiation therapy treatment to fight their individual cancer.

Professor Chris Schofield, Head of the Department of Chemistry, said: “It is absolutely brilliant to attract a scientist of Professor Giaccia’s calibre to Oxford.  His work and expertise perfectly bridge Oxford’s outstanding basic research in cell biology and radiation oncology.”’

Professor Mark Middleton, Head of the Department of Oncology, said:   ‘The Department of Oncology is excited that Professor Giaccia has agreed to join us at such a momentous time to help us secure the future of OIRO and the contribution it makes to the world of radiation oncology’.

Oxford | Emerson Collective Cancer Research Fund – Request for Proposals

The Oxford | Emerson Collective Cancer Research Fund is requesting individual or team proposals for research projects related, but not limited to:

– immunotherapy,
– metabolic therapies,
– early detection advancements,
– ‘high risk/high reward’ initiatives,
– and/or -omic approaches to cancer and drug development.

 

Positive criteria include the potential of a project to significantly impact our understanding of and/or approaches to the prevention, diagnosis, or treatment of cancer.

 

Gift awards range from £50,000 up to £200,000 for up to 2 years for both direct and indirect costs. You may apply for additional funding for the same projects on subsequent RFP rounds, though new projects will be prioritized. This fund does not support incremental research.

Funding will be available early May 2019. Post-award follow-up will entail 12- and 24- month progress and financial reports.

 

Proposals are due on March 8, 2019 at 5 pm EST (see proposal submission guidelines).

 

 

Further details about the fund and application can be accessed here.
The form for budget costs can be accessed via this link.

Proposals need to be submitted via the Emerson Collective’s online submission portal. (Further information on how to access the portal can be found in the documents attached or requested from Claire Bloomfield.)

 

If you plan to share commercially sensitive information in your application please contact Claire Bloomfield to ensure the submission is covered by an Non-disclosure agreement.

 

For further information or questions please contact Claire Bloomfield via Claire.bloomfield@oncology.ox.ac.uk.

 

 

 

 

 

 

 

 

Emerson Collective Website